CNTO-530
| CNTO-530 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CNTO-530 is a biopharmaceutical agent developed for the treatment of anemia, particularly in patients with chronic kidney disease (CKD). It is a type of erythropoiesis-stimulating agent (ESA) designed to stimulate the production of red blood cells by mimicking the action of erythropoietin, a hormone naturally produced by the kidneys.
Mechanism of Action[edit]
CNTO-530 functions by binding to and activating the erythropoietin receptor on the surface of erythroid progenitor cells in the bone marrow. This activation leads to the proliferation and differentiation of these progenitor cells into mature red blood cells, thereby increasing the red blood cell count and improving oxygen delivery to tissues.
Development and Clinical Trials[edit]
CNTO-530 was developed by Janssen Biotech, a subsidiary of Johnson & Johnson. It underwent several phases of clinical trials to evaluate its safety, efficacy, and optimal dosing regimens. The trials primarily focused on patients with anemia due to chronic kidney disease, a condition where the kidneys fail to produce adequate amounts of erythropoietin.
Potential Benefits[edit]
The use of CNTO-530 in treating anemia associated with CKD offers several potential benefits:
- Reduced Need for Blood Transfusions: By stimulating endogenous red blood cell production, CNTO-530 can reduce the need for blood transfusions, which carry risks such as iron overload and transfusion reactions.
- Improved Quality of Life: Anemia can cause symptoms such as fatigue, weakness, and shortness of breath. By alleviating these symptoms, CNTO-530 can improve the quality of life for patients.
Safety and Side Effects[edit]
As with other erythropoiesis-stimulating agents, CNTO-530 may have side effects, including:
- Hypertension: Increased blood pressure is a common side effect due to the increased red blood cell mass.
- Thromboembolic Events: There is a risk of blood clots, which can lead to serious complications such as stroke or myocardial infarction.
Regulatory Status[edit]
As of the latest updates, CNTO-530 has not been approved for general clinical use and remains under investigation. The regulatory status may vary by region and is subject to change based on ongoing research and clinical trial outcomes.
Also see[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
